Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10030-10044

  Li, Ke ^a   Pang, Jun ^a   Cheng, Huaiyan ^b   Liu, Wei Peng ^c   Di, Jin Ming ^a   Xiao, Heng Jun ^a   Luo, Yun ^a   Zhang, Hao ^a   Huang, Wen Tao ^a   Chen, Ming Kun ^a   Li, Liao Yuan ^a   Shao, Chun Kui ^a   Feng, Ying Hong ^b   Gao, Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NANCHANG UNIVERSITY   (China)

Author keywords

CRMP4; Epigenetic manipulation; Metastasis; Prostate cancer; Transcription activator like effectors (TALEs)

Indexed keywords

ANTIMETASTATIC AGENT; CHIMERIC TRANSCRIPTION ACTIVATOR LIKE EFFECTOR DNA DEMETHYLASE; CHIMERIC TRANSCRIPTION ACTIVATOR LIKE EFFECTOR DNA METHYLTRANSFERASE 3A; GELATINASE B; GENOMIC DNA; PROTEIN KINASE B; RAC1 PROTEIN; UNCLASSIFIED DRUG; CRMP-4 PROTEIN, MOUSE; DNA METHYLTRANSFERASE; DPYSL3 PROTEIN, HUMAN; MUSCLE PROTEIN; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; CRMP4 GENE; DEMETHYLATION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION REGULATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATECTOMY; TUMOR SUPPRESSOR GENE; ANIMAL; BAGG ALBINO MOUSE; CASTRATION RESISTANT PROSTATE CANCER; CHLOROCEBUS AETHIOPS; COS CELL LINE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DNA METHYLATION; DNA MODIFICATION METHYLASES; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MUSCLE PROTEINS; NEOPLASM METASTASIS; NERVE TISSUE PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TRANSFECTION;

EID: 84929591106     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3192     Document Type: Article

References (58)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281:1591-1597.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351:1513-1520.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351:1502-1512.
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363:411-422.
5. Yap TA, Pezaro CJ, de Bono JS. Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2012; 12:1129-1136.
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364:1995-2005.
7. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367:1187-1197.
8. Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Prognostic model predicting metastatic castrationresistant prostate cancer survival in men treated with secondline chemotherapy. J Natl Cancer Inst. 2013; 105:1729-1737.
9. Daskivich TJ, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, Greenfield S, Litwin MS. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011; 117:2058-2066.
10. Berger JC, Vander Griend DJ, Robinson VL, Hickson JA, Rinker-Schaeffer CW. Metastasis suppressor genes: from gene identification to protein function and regulation. Cancer Biol Ther. 2005; 4:805-812.
11. Yang H, Yu LR, Yi M, Lucas DA, Lukes L, Lancaster M, Chan KC, Issaq HJ, Stephens RM, Conrads TP, Veenstra TD, Hunter KW. Parallel analysis of transcript and translation profiles: identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications. J Proteome Res. 2006; 5:1555-1567.
12. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010; 28:1069-1078.
13. Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, Helgason CD. The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer. 2012; 11:52.
14. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349:2042-2054.
15. Gao X, Pang J, Li LY, Liu WP, Di JM, Sun QP, Fang YQ, Liu XP, Pu XY, He D, Li MT, Su ZL, Li BY. Expression profiling identifies new function of collaps in response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene. 2010; 29:4555-4566.
16. Sasaki T, Nakamura K, Ogawa K, Onishi H, Okamoto A, Koizumi M, Shioyama Y, Mitsumori M. Radiotherapy for patients with localized hormone-refractory prostate cancer:results of the patterns of care study in Japan. BJU Int. 2009; 104:1462-1466.
17. Pascoe AC, Sundar S. Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer. Radiat Oncol. 2012; 7:43.
18. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010; 116:1908-1918.
19. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodys plastic syndromes. Semin Hematol. 2008; 45:23-30.
20. Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD, Blancafort P. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics. 2012; 7:350-360.
21. Siddique AN, Nunna S, Rajavelu A, Zhang Y, Jurkowska RZ, Reinhardt R, Rots MG, Ragozin S, Jurkowski TP, Jeltsch A. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J Mol Biol. 2013; 425:479-491.
22. Li F, Papworth M, Minczuk M, Rohde C, Zhang Y, Ragozin S, Jeltsch A. Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes. Nucleic Acids Res. 2007; 35:100-112.
23. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009; 326:1509-1512.
24. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by tal effectors. Science. 2009; 326:1501.
25. Bogdanove AJ, Voytas DF. Tal effectors: Customizable proteins for DNA targeting. Science. 2011; 333:1843-1846.
26. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J, Helin K. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature. 2011; 473:343-348.
27. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell. 2011; 145:423-434.
28. Maeder ML, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, Ho QH, Sander JD, Reyon D, Bernstein BE, Costello JF, Wilkinson MF, Joung JK. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol. 2013; 31:1137-1142.
29. Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, Schübeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007; 39:457-466.
30. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgenindependent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004; 64:9209-9216.
31. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res. 2000; 6:1038-1045.
32. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A, Rutka JT. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res. 2005; 65:8792-8800.
33. Binker MG, Binker-Cosen AA, Richards D, Gaisano HY, de Cosen RH, Cosen-Binker LI. Hypoxia-reoxygenation increase invasiveness of PANC-1 cells through Rac1/ MMP-2. Biochem Biophys Res Commun. 2010; 393:371-376.
34. Zhang QG, Wang XT, Han D, Yin XH, Zhang GY, Xu TL. Akt inhibits MLK3/JNK3 signaling by inactivating Rac1:a protective mechanism against ischemic brain injury. J Neurochem. 2006; 98:1886-1898.
35. Kwon T, Kwon DY, Chun J, Kim JH, Kang SS. Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem. 2000; 275:423-428.
36. Furuta E, Bandyopadhyay S, Iiizumi M, Mohinta S, Zhan R, Watabe K. The role of tumor metastasis suppressors in cancers of breast and prostate. Front Biosci. 2006; 11:2845-2860.
37. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003; 3:55-63.
38. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12:895-904.
39. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007; 369:1742-1757.
40. Steger DJ, Lefterova MI, Ying L, Stonestrom AJ, Schupp M, Zhuo D, Vakoc AL, Kim JE, Chen J, Lazar MA, Blobel GA, Vakoc CR. Dot1l/kmt4 recruitment and h3k79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol. 2008; 28:2825-2839.
41. Vaissière T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res. 2008; 659:40-48.
42. Hathaway NA, Bell O, Hodges C, Miller EL, Neel DS, Crabtree GR. Dynamics and memory of heterochromatin in living cells. Cell. 2012; 149:1447-1460.
43. Clark SJ, Melki J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene. 2002; 21:5380-5387.
44. Vaissière T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res. 2008; 659:40-48.
45. Tost J. DNA methylation: methods and protocols. 2nd ed. New York: Humana Press, 2009.
46. Fournier C, Goto Y, Ballestar E, Delaval K, Hever AM, Esteller M, Feil R. Allele- specific histone lysine methylation marks regulatory regions at imprinted mouse genes. EMBO J. 2002; 21:6560-6570.
47. Wang T, Chen M, Liu L, Cheng H, Yan YE, Feng YH, Wang H. Nicotine induced CpG methylation of Pax6 binding motif in StAR promoter reduces the gene expression and cortisol production. Toxicol Appl Pharmacol. 2011; 257:328-337.
48. Yang Y, Liu R, Qiu R, Zheng Y, Huang W, Hu H, Ji Q, He H, Shang Y, Gong Y, Wang Y. CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing. Oncogene. 2015; 34:104-18.
49. Bedell VM, Wang Y, Campbell JM, Poshusta TL, Starker CG, Krug RG 2nd, Tan W, Penheiter SG, Ma AC, Leung AY, Fahrenkrug SC, Carlson DF, Voytas DF, et al. In vivo genome editing using a high-efficiency TALEN system. Nature. 2012; 491:114-118.
50. Sung YH, Baek IJ, Kim DH, Jeon J, Lee J, Lee K, Jeong D, Kim JS, Lee HW. Knockout mice created by TALEN-mediated gene targeting. Nat Biotechnol. 2013; 31:23-24.
51. Deng D, Yan C, Pan X, Mahfouz M, Wang J, Zhu JK, Shi Y, Yan N. Structural basis for sequence-specific recognition of DNA by TAL effectors. Science. 2012; 335:720-723.
52. Klug M, Rehli M. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. Epigenetics. 2006; 1:127-130.
53. Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol. 2011; 29:149-153.
54. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 2011; 29:143-148.
55. Vasiljević N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu YJ, Berney DM, et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers. 2011; 30:151-161.
56. Chen H, Toyooka S, Gazdar AF, Hsieh JT. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J BiolChem. 2003; 278:3121-3130.
57. Drake JM, Gabriel CL, Henry MD. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis. 2005; 22:674-684.
58. Shin YJ, Kim JH. The role of EZH2 in the regulation of the activity of matrix metallo proteinases in prostate cancer cells. PLoS One. 2012; 7:e30393.